NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ANIX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
positive clinical trial results and regulatory approvals | A primary condition in Anixa Biosciences Inc's published investment case. The stated target is successful Phase 1/2 trial results and regulatory approvals. | Intact | trial results fail or regulatory approvals are denied | Qualitative: Phase 1 dose escalation approved & ESMO presentation scheduled Regulatory approval granted for dose escalation; ovarian cancer trial data to be presented at ESMO. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-10-31 · fmp
$-0.33 → $-0.33 · observed estimates
FY2028 revenue: comparable history unavailable.
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making business rather than an established compounder. The thesis state is watch, and confidence in the evidence is low.
The snapshot provides no valuation measure or direct account of market expectations, so whether ANIX is cheap, fair, or expensive versus peers is unclear. Its recent price reaction was up, but the evidence does not show what expectations that reflects.
The recent signal shifted from mixed to mildly favorable, while recent financial performance remains neutral and below its industry cohort. Near term, execution risk is high: the snapshot flags a 47% miss probability for the next print, based on ANIX's smaller size and its industry's high miss rate.
Over the next one to three years, the thesis depends on whether financial performance improves relative to its industry cohort; the snapshot offers little detail on the drivers. A weakening jobs trend could raise recession concerns for cyclical names, while results and guidance from VRTX, REGN, and MRNA could strengthen or weaken the Healthcare sector backdrop. Litigation filings in December 2025 and February 2026 are additional negative events, but their effects are not described.
For the one-to-three-year view, ANIX remains a high-risk, loss-making watch with a modestly improved signal, but the evidence is too limited to establish a stronger fundamental trend. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
earnings per share improves toward break-even |
| A primary condition in Anixa Biosciences Inc's published investment case. The stated target is >= -0.31 USD per share. |
| Improving |
| EPS does not improve beyond -0.31 USD per share by FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
resolution of ongoing litigation without major setbacks | A supporting condition in Anixa Biosciences Inc's published investment case. The stated target is no adverse rulings or settlements harming operations. | Intact | litigation causes major delays or financial harm | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-11-01 | $-0.33 | Unavailable | 2 / 0 |
| 2026-11-02 | $-0.33 | Unavailable | 2 / 0 |
| 2026-11-03 | $-0.33 | Unavailable | 2 / 0 |
| 2026-11-04 | $-0.33 | Unavailable | 2 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.